Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Brighter Outlook for New Cystic Fibrosis Drugs

This article was originally published in Start Up

Executive Summary

The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.

You may also be interested in...



Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

PTC Advances Cystic Fibrosis Candidate On Encouraging Data

Company is pursuing PTC124 in nonsense-mutation-mediated CF, a patient population of about 3,000 in the U.S.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel